A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Trial Profile

A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Registrational; Therapeutic Use
  • Acronyms HERCULES
  • Sponsors Ablynx
  • Most Recent Events

    • 25 Jul 2017 Trial has been completed in Spain.
    • 02 May 2017 According to an Ablynx media release, data from this study will be reported in the second half of 2017 and are expected to support the recently submitted Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA).
    • 02 May 2017 Status changed from recruiting to active, no longer recruiting, according to an Ablynx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top